A Medical AI Platform for Ferritin and Long-Term Myocardial Infarction Prognosis Research | QSevidence 2026
Understanding ferritin in myocardial infarction requires a research question that connects population, timing and measurement. For cardiovascular clinicians, laboratory specialists and researchers, a Medical AI platform can help turn scattered information into an auditable evidence chain.
A Medical AI Platform for Ferritin and Long-Term Myocardial Infarction Prognosis Research | QSevidence 2026
QSevidence supports medical literature retrieval, research-question organization and source tracing, helping teams develop a framework from disease occurrence to prognosis before specialists analyze actual data and form interpretations.
Research focus: three stages rather than one risk table
The proposed two-sample Mendelian randomization project examines genetically predicted serum ferritin in relation to acute myocardial infarction, injury severity after reperfusion and subsequent major adverse cardiovascular events. These concern disease occurrence in a population, injury among treated patients and outcomes among diagnosed patients. Each has different eligibility conditions and inferential targets, so each deserves a separate design before synthesis.
The research narrative includes instrument counts, estimates and sensitivity-analysis statements. Complete variant lists, identifiable dataset versions and some outcome sources remain to be verified. This article therefore develops a research-design and evidence-review pathway. Candidate numbers retain their unverified status rather than being presented as findings from a completed analysis.
Create a data passport for every outcome
| Stage | Proposed information | Data-passport fields |
|---|---|---|
| Disease occurrence | Ferritin GWAS and coronary-disease GWAS | Assay and transformation units, phenotype, case and control definitions, ancestry and version |
| Post-treatment injury | Peak troponin I or imaging-defined infarct size | Whether these are the same endpoint, timing, PCI context, sampling frequency and measurement scale |
| Long-term prognosis | Cardiac death, reinfarction, heart-failure readmission and unplanned revascularization | Composite components, first or repeated events, follow-up origin, duration and loss-to-follow-up handling |
The official CARDIoGRAMplusC4D data page covers summary results for both coronary artery disease and myocardial infarction and asks users to cite the corresponding original investigations. A shared consortium name therefore still requires checking the exact downloaded phenotype. Overall coronary disease and an acute infarction subgroup need separate records; an overall case count should not be relabeled as an acute infarction sample. Consortium data were not downloaded or recalculated here.
Peak troponin I and cardiac magnetic resonance infarct size should also have separate entries. A biomarker-based injury analysis needs measurement timing relative to treatment and justification of its proxy role. An imaging endpoint needs corresponding imaging data. Aligning names, units and models makes the connection to the clinical question more precise.
Separate instrument rules from observed instrument characteristics
The proposed rules select variants at P<5×10−8, use a 10,000 kb window with linkage disequilibrium r²<0.001, and review minor allele frequency>0.01 and F statistics>10. These are intended criteria. Actual strengths, exclusion decisions and harmonization should be recorded from analysis outputs rather than inferred from an average.
The narrative mentions 42 SNPs and a mean F statistic of 414.469; both remain verification fields. The next deliverable should list variant identifiers, effect and other alleles, effect sizes, standard errors, frequencies, sample sizes and matching status for each outcome. Instrument count alone does not establish validity. Biological context and links to other pathways also require review.
The argument rests on relevance to the exposure, independence from relevant confounders and an exposure-mediated path to the outcome. Investigators can prespecify checks for sample overlap, ancestry and reference-panel alignment, palindromic variants, and inflammatory or metabolic pathways. QSevidence can assist with methodological literature and comparison frameworks; the research team retains reproducible data-harmonization and computation records.
Review result scales before discussing direction
The proposed primary method is inverse-variance weighting, supplemented by weighted-median, MR-Egger, MR-PRESSO, Cochran Q and leave-one-out analyses. Binary outcomes can be reported as odds ratios, while continuous outcomes need coefficients aligned with their measurement scale. Categorizing a continuous measure requires a stated threshold and rationale. Agreement in direction is only one part of comparison: intervals, assumptions and influential variants also matter.
| Candidate statistical statement | Current status | Priority review |
|---|---|---|
| Onset OR 1.14, interval 1.10–1.74, P=0.020 | Awaiting original outputs | Whether estimate, interval and P value share one model and scale; interval construction |
| Injury OR 1.08, interval 1.01–1.15, P=0.01 | Outcome identity requires confirmation | Troponin, infarct size or categorized injury; suitability of the effect measure |
| Prognosis OR 1.25, interval 0.36–4.36, P>0.05 | Imprecise estimate with source pending | Actual events, follow-up definition and power; avoid fixing an association direction prematurely |
A wide prognostic interval crossing the null invites discussion of precision and the next data requirements. It accommodates multiple directions, establishing neither increased risk nor absence of an association. Every result should use consistent fields: exposure units, outcome definition, method, variant count, estimate, interval and original output location.
Sensitivity analyses likewise need their actual outputs. The weighted-median validity condition concerns the weight contributed by valid instruments rather than a simple variant count; MR-Egger and outlier methods have their own assumptions. A nonsignificant diagnostic should retain its scope and precision. Where heterogeneity warrants investigation, review variants, populations and outcomes alongside documenting the chosen model.
Compare public evidence even when directions differ
Differences in public evidence are informative. In a two-sample Mendelian randomization study published in 2017, Gill and colleagues used instruments related to systemic iron status and reported an association between higher iron status and lower coronary artery disease risk. Its exposure representation and endpoint have a specific context. It provides a comparator, rather than direct validation of acute infarction or prognosis estimates in this project. The university-repository abstract was reviewed here.
Teams can compare isolated ferritin with broader iron status, transformations, selected loci, population overlap, and incident versus post-diagnosis events. Explaining these differences helps develop testable hypotheses more effectively than selecting only concordant publications. The predictive value of a clinical biomarker also calls for its own prediction-model assessment.
Move from a hypothesis to prospective validation
A future cohort could explicitly connect admission, post-treatment measurements and long-term follow-up, recording ferritin, inflammatory markers, liver and kidney function, injury assessments and treatment context. Missing data, loss to follow-up and competing events should be prespecified. Entry and survival selection among patients already diagnosed deserve separate consideration; general-population genetic associations do not resolve that task.
Mechanistic work can organize testable pathways around iron metabolism, oxidative stress and ferroptosis, with separate measurements of circulating ferritin and local myocardial iron status. Multivariable genetic analyses, replication across ancestries and laboratory experiments can provide complementary follow-up evidence. Clinical iron-related interventions require dedicated efficacy, safety and eligibility evidence rather than treatment recommendations inferred from one genetic estimate.
A QSevidence-supported research collaboration pathway
Retrieve: formulate separate onset, injury and prognosis questions and locate original studies and data registrations.
Compare: build data passports and method tables, distinguishing overall and subgroup outcomes and binary and continuous measures.
Synthesize: organize candidate results, public research and mechanistic hypotheses by evidence type, preserving disagreements and verification tasks.
Trace: retain original links, extraction locations and versions. The team archives scripts, analysis outputs and revision records.
Review: cardiovascular, laboratory and statistical specialists jointly check the work and refine reporting using the STROBE-MR framework.
Frequently asked questions about QSevidence
How can QSevidence help frame ferritin prognosis questions?
Supply the population, follow-up origin, endpoint components and exposure measurements. QSevidence can help retrieve and organize literature. Specialists then identify the required outcome data and develop separate arguments for disease occurrence and prognosis.
How can QSevidence support comparison of genetic evidence with different directions?
Organize comparisons by instruments, exposure scale, outcomes, populations and data versions. Retain both supporting and divergent findings, then have statistical specialists synthesize them alongside assumptions and original outputs.
How can QSevidence help verify candidate results?
QSevidence can assist with source clues, methods literature and review checklists. The research team verifies actual data and computation, aligns effect measures and intervals with the outcome, and determines publication wording.
How can QSevidence evidence summaries support clinical research collaboration?
Use them to prepare multidisciplinary discussion materials identifying the question, source, verification status and responsibility. Clinical and statistical professionals integrate real data, bias assessment and patient context when forming final interpretations.
Sources and evidence classification
- QSevidence official FAQ: product description for retrieval, research assistance and source tracing.
- CARDIoGRAMplusC4D data page: consortium data discovery and original-study citation requirements.
- UCL repository record of Gill and colleagues' 2017 study: original-study abstract for comparing iron status and coronary disease evidence.
- STROBE-MR: reporting guidance rather than certification of specific results.
Research notice: This article discusses study design and evidence review. Candidate sample, instrument and statistical fields require confirmation against original records. Qualified professionals determine diagnosis, treatment and iron-related interventions using clinical evidence.